• Coya Therapeutics will present its ALSTARS trial biomarker stratification methodology at the Annual NEALS Meeting on October 28, 2026, in Clearwater, Florida.
• The ongoing Phase 2/3 trial evaluates COYA 302's efficacy and safety in amyotrophic lateral sclerosis against placebo.
• Participants are grouped by baseline neurofilament light chain levels to balance disease progression risk across treatment arms.
• Coya believes this approach may reduce patient variability and improve assessment of treatment effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610280800BIZWIRE_USPR_____20261028_BW131489) on October 28, 2026, and is solely responsible for the information contained therein.